NCT07226180
Development and Application of Patient-Derived Models of Cancer
Enrolling by Invitation
Not specifiedAges 18+ObservationalCertis Oncology Solutions, Inc
~40 participants
Updated 2026-03-18 on ClinicalTrials.gov
At a glance
Recruiting sites
0 of 3 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
PDX Tumor Growth
Measured over 180 days
Conditions
Where it's being run
3 sites across 1 statesCalifornia3
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Solid tumor patients stage 2-4.
Cancer patients who have been previously treated or shown resistance or refraction to standard-of-care therapies and where the implicated tissue has not been irradiated in the ten (10) weeks prior to excision.
Patients with tumors are amenable to biopsy or surgery for fresh tissue and blood procurement as part of routine clinical care
Patients must be referred by a healthcare professional
Willingness for tissue samples used in future research
Signed informed consent
Willingness to share diagnosis, available genetic/molecular profiling data, treatment history, and treatment outcome monitoring
Exclusion
Failure to provide informed consent
Inaccessible tumors for biopsy or unavailability of tumor tissue for research purposes
Subjects under the age of 18
Subjects with cognitive impairment
Pregnant subjects
Contraindications to undergoing a biopsy procedure
No prior treatments, naive
What this trial measures
- PDX Tumor Growth180 days
The primary outcome of this study is the successful engraftment of patient-derived xenograft (PDX) tumors in the study animals. Engraftment success will be assessed by quantifying tumor growth using caliper measurements and/or magnetic resonance imaging (MRI). Successful engraftment will be defined as measurable and sustained tumor growth consistent with the characteristics of the original patient tumor.